|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By




From the * Department of Microbiology, Tokyo Medical and Dental University School of Medicine,
Bunkyo-ku, Tokyo 113, Japan; Several members of the chemokine receptor family have been shown to function in association
with CD4 to permit human immunodeficiency virus type 1 (HIV-1) entry and infection. The
CXC chemokine receptor CXCR4/fusin is a receptor for pre-B cell growth stimulating factor (PBSF)/stromal cell-derived factor 1 (SDF-1) and serves as a coreceptor for the entry of T cell
line-tropic HIV-1 strains. Thus, the development of CXCR4 antagonists or agonists may be
useful in the treatment of HIV-1 infection. T22 ([Tyr5,12,Lys7]-polyphemusin II) is a synthesized peptide that consists of 18 amino acid residues and an analogue of polyphemusin II isolated from the hemocyte debris of American horseshoe crabs (Limulus polyphemus). T22 was
found to specifically inhibit the ability of T cell line-tropic HIV-1 to induce cell fusion and infect the cell lines transfected with CXCR4 and CD4 or peripheral blood mononuclear cells. In
addition, T22 inhibited Ca2+ mobilization induced by pre-B cell growth stimulating factor (PBSF)/SDF-1 stimulation through CXCR4. Thus, T22 is a small molecule CXCR4 inhibitor
that blocks T cell line-tropic HIV-1 entry into target cells.
Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu,
Osaka 566, Japan; § Department of Immunology, Research Institute, Osaka Medical Center for
Maternal and Child Health, 840 Murodo-cho, Izumi, Osaka 590-02, Japan; and
Faculty of
Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606, Japan; ¶ SEIKAGAKU Corp.,
Chyuo-ku, Tokyo 103, Japan; ** Department of Medicine III, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565, Japan
This article has been cited by other articles:
| TABLE OF CONTENTS |
|